A composite screening tool for medication reviews of outpatients: General issues with specific examples

Drugs and Aging

Volumn 24, Issue 9, 2007, Pages 733-760

  De Smet, Peter A G M ^a,b   Denneboom, Wilma ^b,c   Kramers, Cees ^d   Grol, Richard ^b  

^a Scientific Institute Dutch Pharmacists   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Apotheek Meindersma   (Netherlands)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAHISTINE; CALCIUM CHANNEL BLOCKING AGENT; CHLORAMPHENICOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIGOXIN; DIHYDROERGOTOXINE MESILATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EXPECTORANT AGENT; GLIBENCLAMIDE; HYDROQUININE; LEVODOPA; METHOTREXATE; METOCLOPRAMIDE; MUCOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PIRACETAM; POTASSIUM; QUININE; SPASMOLYTIC AGENT; SULFONYLUREA; THEOPHYLLINE; UNINDEXED DRUG; VASODILATOR AGENT; WARFARIN;

BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLAUDICATION; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEMENTIA; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DOSAGE FORM COMPARISON; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HEALTH CARE PERSONNEL; HUMAN; INFORMATION DISSEMINATION; IRRITABLE COLON; KIDNEY FUNCTION; LABORATORY TEST; MEDICAL RESEARCH; MENIERE DISEASE; OUTPATIENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCREENING; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; DOSAGE FORMS; DRUG INTERACTIONS; DRUG PACKAGING; DRUG UTILIZATION REVIEW; GERIATRICS; HUMANS; MEDICATION ERRORS; OUTPATIENTS; POLYPHARMACY; PRESCRIPTIONS, DRUG; THERAPEUTIC EQUIVALENCY; TREATMENT REFUSAL;

EID: 34548479060     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724090-00003     Document Type: Review

References (354)

1. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging 2003; 20 (11): 817-32
2. De Smet PAGM, Dautzenberg M. Repeat prescribing: scale, problems and quality management in ambulatory care patients. Drugs 2004; 64: 1779-800
3. Merle L, Laroche ML, Dantoine T, et al. Predicting and preventing adverse drug reactions in the very old. Drugs Aging 2005; 22 (5): 375-92
4. Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med 1996 Apr; 100 (4): 428-37
5. Stewart S, Pearson S, Luke CG, et al. Effects of home-based intervention on unplanned readmissions and out-of-hospital deaths. J Am Geriatr Soc 1998 Feb; 46 (2): 174-80
6. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000 Dec; 20 (12): 1508-16
7. Lowe CJ, Raynor DK, Purvis J, et al. Effects of a medicine review and education programme for older people in general practice. Br J Clin Pharmacol 2000 Aug; 50 (2): 172-5
8. Zermansky AG, Petty DR, Raynor DK, et al. Randomised controlled trial of clinical medication review by a pharmacist of elderly patients receiving repeat prescriptions in general practice. BMJ 2001 Dec 8; 323 (7325): 1340-3
9. Sorensen L, Stokes JA, Purdie DM, et al. Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol 2004 Dec; 58 (6): 648-64
10. Holland R, Lenaghan E, Harvey I, et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ 2005 Feb 5; 330 (7486): 293
11. Medicare Australia. Home medicines review [online]. Available from URL: http://www.medicareaustralia.gov.au/providers/incentives_allowances/ pharmacy_agreement/hmr.htm [Accessed 2005 Dec 28]
12. Bos E. Polyfarmacieproject bespaart kosten: achmea betaalt voor zorgactiviteiten polyfarmacieproject. Pharm Weekbl 2005; 140: 1052-3
13. Kring en VGZ sluiten contract: Zorgverzekeraar VGZ maakt Kring-apotheken voorkeursleverancier voor vijf jaar. Pharm Weekbl 2005; 140: 1510-1
14. Directions: the National Health Service Act 1977: the pharmaceutical services (advanced and enhanced services) (England) directions 2005. London: Department of Health, 2005
15. Shaw J, Seal R, Pilling M. Room for review: a guide to medication review: the agenda for patients, practitioners and managers. Task Force on Medicines Partnership and the National Collaborative Medicines Management Services Programme. London: Medicines Partnership, 2002
16. Denneboom W, Dautzenberg MG, Grol R, et al. Analysis of polypharmacy in older patients in primary care using a multidisciplinary expert panel. Br J Gen Pract 2006 Jul; 5 (528): 504-10
17. Denneboom W, Dautzenberg MG, Grol R, et al. User-related pharmaceutical care problems and factors affecting them: the importance of clinical relevance. J Clin Pharm Ther 2005 Jun; 30 (3): 215-23
18. Shelton PS, Fritsch MA, Scott MA. Assessing medication appropriateness in the elderly: a review of available measures. Drugs Aging 2000 Jun; 16 (6): 437-50
19. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents: UCLA Division of Geriatric Medicine. Arch Intern Med 1991 Sep; 151 (9): 1825-32
20. Aparasu RR, Mort JR. Inappropriate prescribing for the elderly: Beers criteria-based review. Ann Pharmacother 2000 Mar; 34 (3): 338-46
21. Viswanathan H, Bharmal M, Thomas III J. Prevalence and correlates of potentially inappropriate prescribing among ambulatory older patients in the year 2001: comparison of three explicit criteria. Clin Ther 2005 Jan; 27 (1): 88-99
22. Fialov́a D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005 Mar 16; 293 (11): 1348-58
23. Van der Hooft CS, Jong GW, Dieleman JP, et al. Inappropriate drug prescribing in older adults: the updated 2002 Beers criteria: a population-based cohort study. Br J Clin Pharmacol 2005 Aug; 60 (2): 137-44
24. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001 Dec 12; 286 (22): 2823-9
25. Pugh MJ, Fincke BG, Bierman AS, et al. Potentially inappropriate prescribing in elderly veterans: are we using the wrong drug, wrong dose, or wrong duration? J Am Geriatr Soc 2005 Aug; 53 (8): 1282-9
26. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003 Dec 8; 163 (22): 2716-24
27. Kassam R, Martin LG, Farris KB. Reliability of a modified medication appropriateness index in community pharmacies. Ann Pharmacother 2003 Jan; 37 (1): 40-6
28. Hanlon JT, Artz MB, Pieper CF, et al. Inappropriate medication use among frail elderly inpatients. Ann Pharmacother 2004 Jan; 38 (1): 9-14
29. Bregnhøj L, Thirstrup S, Kristensen MB, et al. Reliability of a modified medication appropriateness index in primary care. Eur J Clin Pharmacol 2005 Nov; 61 (10): 769-73
30. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992 Oct; 45 (10): 1045-51
31. Fitzgerald LS, Hanlon JT, Shelton PS, et al. Reliability of a modified medication appropriateness index in ambulatory older persons. Ann Pharmacother 1997 May; 31 (5): 543-8
32. Knight EL, Avorn J. Quality indicators for appropriate medication use in vulnerable elders. Ann Intern Med 2001 Oct 16; 135 (8 Pt 2): 703-10
33. Sellors J, Kaczorowski J, Sellors C, et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ 2003 Jul 8; 169 (1): 17-22
34. Wenger NS, Solomon DH, Roth CP, et al. The quality of medical care provided to vulnerable community-dwelling older patients. Ann Intern Med 2003 Nov 4; 139 (9): 740-7
35. Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med 2004 May 4; 140 (9): 714-20
36. Shekelle PG, MacLean CH, Morton SC, et al. Assessing care of vulnerable elders: methods for developing quality indicators. Ann Intern Med 2001 Oct 16; 135 (8 Pt 2): 647-52
37. MacLean CH. Quality indicators for the management of osteoarthritis in vulnerable elders. Ann Intern Med 2001 Oct 16; 135 (8 Pt 2): 711-21
38. McGavock H, Wilson-Davis K, Connolly JP. Repeat prescribing management: a cause for concern? Br J Gen Pract 1999 May; 49 (442): 343-7
39. Robertson HA, MacKinnon NJ. Development of a list of consensus-approved clinical indicators of preventable drug-related morbidity in older adults. Clin Ther 2002 Oct; 24 (10): 1595-613
40. Oborne CA, Hooper R, Swift CG, et al. Explicit, evidence-based criteria to assess the quality of prescribing to elderly nursing home residents. Age Ageing 2003 Jan; 32 (1): 102-8
41. Woodward MC. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract Res 2003; 33: 323-8
42. Le Couteur DG, Hilmer SN, Glasgow N, et al. Prescribing in older people. Aust Fam Physician 2004 Oct; 33 (10): 777-81
43. Farris KB, Ganther-Urmie JM, Fang G, et al. Population-based medication reviews: a descriptive analysis of the medication issues identified in a Medicare not-for-profit prescription discount program. Ann Pharmacother 2004 Nov; 38 (11): 1823-9
44. Bushardt RL, Jones KW. Nine key questions to address polypharmacy in the elderly. JAAPA 2005 May; 18 (5): 32-7
45. Murphy JE. Generic substitution and optimal patient care. Arch Intern Med 1999 Mar 8; 159 (5): 429-33
46. Suh DC. Trends of generic substitution in community pharmacies. Pharm World Sci 1999 Dec; 21 (6): 260-5
47. De Smet PAGM. Leidraad geneesmiddelsubstitutie: Een medisch- farmaceutische leidraad. 's-Gravenhage: Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie, 1990
48. Meyer MC. Generic drug product equivalence: current status. Am J Manag Care 1998 Aug; 4 (8): 1183-9
49. Generic drugs. Med Lett Drugs Ther 2002 Oct 14; 44 (1141): 89-90
50. Schall R, Muller FR, Muller FO, et al. Bioequivalence of controlled-release calcium antagonists. Clin Pharmacokinet 1997 Jan; 32 (1): 75-89
51. Bialer M, Yacobi A, Moros D, et al. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 1998 May; 39 (5): 513-9
52. Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf 2000 Sep; 23 (3): 173-82
53. Olling M, Mensinga TT, Barends DM, et al. Bioavailability of carbamazepine from four different products and the occured rence of side effects. Biopharm Drug Dispos 1999 Jan; 20 (1): 19-28
54. Halkin H, Shapiro J, Kurnik D, et al. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther 2003 Sep; 74 (3): 215-21
55. Hielema AP, De Smet PAGM. Diversiteit van bijsluiters als obstakel bij substitutie. Pharm Weekbl 1991; 126: 504-6
56. Tinke JL, De Smet PAGM. Data en feiten over generieke substitutie en therapeutische standaardisatie. Pharm Weekbl 1997; 132: 290-4
57. Hilleman DE, Wurdeman RL, Lenz TL. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. Pharmacotherapy 2001 Apr; 21 (4): 410-5
58. McAlister FA, Laupacis A, Wells GA, et al. Users' guides to the medical literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999 Oct 13; 282 (14): 1371-7
59. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 1999 Oct 2; 354 (9185): 1202-4
60. De Smet PAGM, Van der Kuy A, Bonsel GJ. Mogelijkheden en beperkingen van klassesubstitutie als doelmatigheidsinstrument in de geneesmiddelenvoorziening. Ned Tijdschr Geneeskd 2002 Mar 23; 146 (12): 553-7
61. Soriano JB, Hoes AW, Meems L, et al. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997 Mar; 39 (5): 445-56
62. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999 Jun 26; 318 (7200): 1730-7
63. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004 Nov 6; 364 (9446): 1684-9
64. Levy RA, Smith DL. Clinical differences among nonsteroidal antiinflammatory drugs: implications for therapeutic substitution in ambulatory patients. DICP 1989 Jan; 23 (1): 76-85
65. Henry D, Lim LL, Garcia RL, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996 Jun 22; 312 (7046): 1563-6
66. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998 Dec 5; 352 (9143): 1830-1
67. Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing 2001 May; 30 (3): 205-11
68. Warholak-Juarez T, Rupp MT, Salazar TA, et al. Effect of patient information on the quality of pharmacists' drug use review decisions. J Am Pharm Assoc (Wash) 2000 Jul; 40 (4): 500-8
69. Olin J, Schneider L, Novit A, et al. Hydergine for dementia. Cochrane Database Syst Rev 2001 Jan; (2): CD000359
70. Flicker L, Grimley EG. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2001; (2): CD001011
71. James AL, Burton MJ. Betahistine for Meniere's disease or syndrome. Cochrane Database Syst Rev 2001 Jan; (2): CD001873
72. De Backer TL, Van der Stichele RH, Warie HH, et al. Oral vasoactive medication in intermittent claudication: utile or futile? Eur J Clin Pharmacol 2000 Jun; 56 (3): 199-206
73. Moher D, Pham B, Ausejo M, et al. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 2000 May; 59 (5): 1057-70
74. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001 Feb; 48 (2): 272-82
75. Knutson D, Braun C. Diagnosis and management of acute bronchitis. Am Fam Physician 2002 May 15; 65 (10): 2039-44
76. Polk B. Expectorants: help for acute cold bronchitis? Med Monatsschr Pharm 2002 Nov; 25 (11): 379-81
77. Walters J, Walters E, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; (3): CD005374
78. De Smet PAGM. Drug therapy: herbal remedies. N Engl J Med 2002 Dec 19; 347 (25): 2046-56
79. Yeh GY, Eisenberg DM, Kaptchuk TJ, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003 Apr; 26 (4): 1277-94
80. Homeopathy again: a questionable meta-analysis. Prescrire Int 1998 Jun; 7 (35): 94-5
81. Shang A, Huwiler-Muntener K, Nartey L, et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet 2005 Aug 27; 366 (9487): 726-32
82. Gerety MB, Cornell JE, Plichta DT, et al. Adverse events related to drugs and drug withdrawal in nursing home residents. J Am Geriatr Soc 1993 Dec; 41 (12): 1326-32
83. Graves T, Hanlon JT, Schmader KE, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med 1997 Oct 27; 157 (19): 2205-10
84. van Kraaij DJ, Jansen RW, Gribnau FW, et al. Loop diuretics in patients aged 75 years or older: general practitioners' assessment of indications and possibilities for withdrawal. Eur J Clin Pharmacol 1998 Jun; 54 (4): 323-7
85. Hurenkamp GJB, Grundmeijer HGLM, Bindels PJE, et al. Chronisch gebruik van maagzuursecretieremmende medicatie in de huisartsenpraktijk in de regio Amsterdam. Ned Tijdschr Geneeskd 1999 Feb 20; 143 (8): 410-3
86. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001 Jun; 23 (3): 116-7
87. Hurenkamp GJB, Grundmeijer HGLM, Van der Ende A, et al. Afbouw van langdurig gebruik van maagzuurremmers is mogelijk. Huisarts Wet 2003; 46 (7): 354-8
88. Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther 2004 Apr 15; 19 (8): 917-22
89. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006 Dec 27; 296 (24): 2947-53
90. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003 Sep 16; 169 (6): 557-64
91. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004 Oct; 19 (10): 919-25
92. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence, 2001
93. Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003 Apr 19; 326 (7394): 841-4
94. Froom J, Trilling J. Reducing antihypertensive medication use in nursing home patients. Arch Fam Med 2000 Apr; 9 (4): 378-83
95. Elliott WJ. Management of hypertension in the very elderly patient. Hypertension 2004 Dec; 44 (6): 800-4
96. Kapoor JR, Chaudry S, Agostini JV, et al. Systolic hypertension in older persons: how aggressive should treatment be? Prog Cardiovasc Dis 2006 May; 48 (6): 397-406
97. Bulpitt CJ, Beckett NS, Cooke J, et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003 Dec; 21 (12): 2409-17
98. Poole PJ, Black PN. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am J Respir Med 2003; 2 (5): 367-70
99. Hamdy RC, Moore SW, Whalen K, et al. Reducing polypharmacy in extended care. South Med J 1995 May; 88 (5): 534-8
100. Williams BR, Nichol MB, Lowe B, et al. Medication use in residential care facilities for the elderly. Ann Pharmacother 1999 Feb; 33 (2): 149-55
101. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999 Jun 17; 340 (24): 1888-99
102. Sweetman SC. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press, 2005
103. Paulino EI, Bouvy ML, Gastelurrutia MA, et al. Drug related problems identified by European community pharmacists in patients discharged from hospital. Pharm World Sci 2004 Dec; 26 (6): 353-60
104. Stewart RB, Cooper JW. Polypharmacy in the aged: practical solutions. Drugs Aging 1994 Jun; 4 (6): 449-61
105. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997 Oct 25; 315 (7115): 1096-9
106. Chow SL, Luzier AB, DiTusa L, et al. Acid-suppressive therapy use associated with antihypertensive agents. J Clin Pharmacol 2001 Jul; 41 (7): 750-6
107. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006 Jan; 129 (1 Suppl.): 169-173S
108. Kogut SJ, El Maouche D, Abughosh SM. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy 2005; 25 (12): 1729-35
109. Steele AC, Kohli N, Mallipeddi P, et al. Pharmacologic causes of female incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10 (2): 106-10
110. Schneider T, Rubben H, Michel MC. Die medikamenten-induzierte Dysfunktion der Harnblase. Urologe A 2003 Dec; 42 (12): 1588-93
111. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc 2002 May; 50 (5): 836-42
112. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 2005 Apr 11; 165 (7): 808-13
113. Movig KL, Leufkens HG, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002 Jun; 11 (4): 271-9
114. Ness J, Hoth A, Barnett MJ, et al. Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. Am J Geriatr Pharmacother 2006 Mar; 4 (1): 42-51
115. Janssens HJ, van de Lisdonk EH, Janssen M, et al. Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis 2006 Aug; 65 (8): 1080-3
116. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997 Jul 28; 157 (14): 1531-6
117. Kunin CM. Inappropriate medication use in older adults: does nitrofurantoin belong on the list for the reasons stated? [letter]. Arch Intern Med 2004 Aug 9; 164 (15): 1701
118. White WT, Harrison L, Dumas J. Nitrofurantoin unmasking peripheral neuropathy in a type 2 diabetic patient. Arch Intern Med 1984 Apr; 144 (4): 821
119. Volbeda F, Jonker AM, Vecht J, et al. Levercirrose door chronisch gebruik van nitrofurantöine. Ned Tijdschr Geneeskd 2004 Jan 31; 148 (5): 235-8
120. Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging 2003; 20 (1): 23-57
121. Graal MB, Wolffenbuttel BH. The use of sulphonylureas in the elderly. Drugs Aging 1999 Dec; 15 (6): 471-81
122. Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999 Jul; 16 (7): 586-90
123. Veitch PC, Clifton-Bligh RJ. Long-acting sulfonylureas: long-acting hypoglycaemia. Med J Aust 2004 Jan 19; 180 (2): 84-5
124. Newnham DM. Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. Drug Saf 2001; 24 (14): 1065-80
125. Yohannes AM, Hardy CC. Treatment of chronic obstructive pulmonary disease in older patients: a practical guide. Drugs Aging 2003; 20 (3): 209-28
126. Ohnishi A, Kato M, Kojima J, et al. Differential pharmacokinetics of theophylline in elderly patients. Drugs Aging 2003; 20 (1): 71-84
127. van Kan HJ, Jansen PH, Tuinte C, et al. Hydroquinine pharmacokinetics after oral administration in adult patients with muscle cramps. Eur J Clin Pharmacol 2000 Jun; 56 (3): 263-7
128. Brinker AD, Beitz J. Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action. Am J Hematol 2002 Aug; 70 (4): 313-7
129. Managing patients with restless legs. Drug Ther Bull 2003 Nov; 41 (11): 81-3
130. Van Marum RJ, Jansen PA. Toegenomen kans op een beroerte na gebruik van olanzapine of risperidon bij patïenten met dementie. Ned Tijdschr Geneeskd 2005 Jan 22; 149 (4): 165-7
131. Carnahan RM, Lund BC, Perry PJ, et al. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand 2006 Feb; 113 (2): 135-41
132. Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2005 Sep 12; 165 (16): 1882-8
133. Shah RR. Drug development and use in the elderly: search for the right dose and dosing regimen (parts I and II). Br J Clin Pharmacol 2004 Nov; 58 (5): 452-69
134. Kinirons MT, O'Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004 May; 57 (5): 540-4
135. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004 Feb; 57 (2): 121-6
136. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004 Jan; 57 (1): 6-14
137. Cohen JS. Avoiding adverse reactions: effective lower-dose drug therapies for older patients. Geriatrics 2000 Feb; 55 (2): 54-60, 63
138. Lackner TE, Heard T, Glunz S, et al. Gastrointestinal disease control after histamine2-receptor antagonist dose modification Befor renal impairment in frail chronically ill elderly patients. J Am Geriatr Soc 2003 May; 51 (5): 650-6
139. Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000 Mar; 16 (3): 165-77
140. Gosselink AT, van Veldhuisen DJ, Crijns HJ. When, and when not, to use digoxin in the elderly. Drugs Aging 1997 Jun; 10 (6): 411-20
141. Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician 1998 Jan 1; 57 (1): 107-16
142. Hoogendam A, Hofmeijer J, Frijns CJ, et al. Ernstig parkinsonisme ten gevolge van metoclopramide bij een patïente met polyfarmacie. Ned Tijdschr Geneeskd 2002 Jan 26; 146 (4): 175-7
143. Touw DJ. Metabolisme van clomipramine. Pharm Weekbl 1992; 127: 1068-74
144. Dorhout-Doude van Troostwijk LJAE, Koopmans RP, Vermeulen HDB, et al. CYP1A2 en de klaring van clozapine: hulpmiddel ter bepaling van de dosis. Pharm Weekbl 2001; 136: 1439-42
145. Jansen PAF. Valkuilen bij medicatiegebruik door ouderen. Geneesmiddelenbulletin 2000; 34: 53-9
146. Jansen PAF. Werkgroep klinische gerontofarmacologie: geneesmiddelen interacties bij ouderen: welke zijn klinisch relevant? Ned Tijdschr Geneeskd 2003; 147: 595-9
147. Herings RM, Stricker BH, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995 Sep 11; 155 (16): 1801-7
148. Wang PS, Bohn RL, Glynn RJ, et al. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001 Jun; 158 (6): 892-8
149. Rochon PA, Clark JP, Gurwitz JH. Challenges of prescribing low-dose drug therapy for older people. CMAJ 1999 Apr 6; 160 (7): 1029-31
150. Gurwitz JH, Monette J, Rochon PA, et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997 May 12; 157 (9): 978-84
151. Rodenhuis N, De Smet PAGM, Barends DM. Patient experiences with the performance of tablet score lines needed for dosing. Pharm World Sci 2003 Aug; 25 (4): 173-6
152. Rodenhuis N, De Smet PAGM, Barends DM. The rationale of scored tablets as dosage form. Eur J Pharm Sci 2004; 21: 305-8
153. Lapane KL, Hughes CM. Pharmacotherapy interventions undertaken by pharmacists in the Fleetwood phase III study: the role of process control. Ann Pharmacother 2006 Sep; 40 (9): 1522-6
154. Macfarlane J, Prewett J, Rose D, et al. Prospective case-control study of role of infection in patients who reconsult after initial antibiotic treatment for lower respiratory tract infection in primary care. BMJ 1997 Nov 8; 315 (7117): 1206-10
155. Schulman S. Clinical practice: care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003 Aug 14; 349 (7): 675-83
156. Batty GM, Oborne CA, Swift CG, et al. Development of an indicator to identify inappropriate use of benzodiazepines in elderly medical in-patients. Int J Geriatr Psychiatry 2000 Oct; 15 (10): 892-6
157. Woodward MC. Hypnotics: options to help your patients stop. Aust Fam Physician 2000; 29: 939-44
158. Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Behandelmethoden om langdurig benzodiazepinegebruik te staken. Ned Tijdschr Geneeskd 2001 Jul 14; 145 (28): 1347-50
159. Haumschild MJ, Karfonta TL, Haumschild MS, et al. Clinical and economic outcomes of a fall-focused pharmaceutical intervention program. Am J Health Syst Pharm 2003 May 15; 60 (10): 1029-32
160. Gorgels WJ, Oude Voshaar RC, Mol AJ, et al. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend 2005 Apr 4; 78 (1): 49-56
161. Hirschfeld RM. Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 403: 35-8
162. Fremont P. Drug use in the elderly: use of psychotropic drugs in the elderly: overuse or underuse? Presse Med 1999 Oct 23; 28 (32): 1794-9
163. McLeod PJ, Huang AR, Tamblyn RM, et al. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ 1997 Feb 1; 156 (3): 385-91
164. Lindblad CI, Artz MB, Pieper CF, et al. Potential drug-disease interactions in frail, hospitalized elderly veterans. Ann Pharmacother 2005 Mar; 39 (3): 412-7
165. Zhan C, Correa-de-Araujo R, Bierman AS, et al. Suboptimal prescribing in elderly outpatients: potentially harmful drug-drug and drug-disease combinations. J Am Geriatr Soc 2005 Feb; 53 (2): 262-7
166. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005 Aug 10; 294 (6): 716-24
167. Buurma H, De Smet PAGM, Kruijtbosch M, et al. Disease and intolerability documentation in electronic patient records. Ann Pharmacother 2005 Oct; 39 (10): 1640-6
168. Gray J, Majeed A, Kerry S, et al. Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records. BMJ 2000 Sep 2; 321 (7260): 548-50
169. Shakib S, George A. Monitoring: to infinity and beyond! Aust Fam Physician 2003 Dec; 32 (12): 995-7
170. Questions and answers on COX-2 inhibitors. Press office European Medicines Agency, London, 27 June 2005, doc. ref. EMEA/210745/2005 corr [online]. Available from URL: http://www.emea.eu.int/pdfs/human/press/pr/ 21074505en.pdf [Accessed 2005 Aug 18]
171. Stockley IH. Drug interactions. 6th ed. London: Pharmaceutical Press, 2002
172. Hansten PD, Horn JR. The top 100 drug interactions: a guide to patient management. Edmonds (WA): H&H Publications, 2005
173. Tatro DS. Drug interaction facts 2005: the authority on drug interactions. St Louis (MA): Facts and Comparisons, 2005
174. Buurma H, De Smet PAGM, Egberts AC. Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. Drug Saf 2006; 29 (8): 723-32
175. De Gier J. Commentaren Medicatiebewaking 2006/2007. Houten: Health Base, 2006
176. Malone DC, Abarca J, Hansten PD, et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. J Am Pharm Assoc 2004 Mar; 44 (2): 142-51
177. Malone DC, Hutchins DS, Haupert H, et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005 Oct 1; 62 (19): 1983-91
178. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003 Apr 2; 289 (13): 1652-8
179. Gúedon-Moreau L, Ducrocq D, Duc MF, et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2003 Nov; 59 (8-9): 689-95
180. Gúedon-Moreau L, Ducrocq D, Duc MF, et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2004 Feb; 59 (12): 899-904
181. Becker ML, Kallewaard M, Caspers PW, et al. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf 2005; 28 (5): 371-8
182. Chen YF, Avery AJ, Neil KE, et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005; 28 (1): 67-80
183. Mathew TH. Drug-induced renal disease. Med J Aust 1992 May 18; 156 (10): 724-8
184. Thomas MC. Diuretics, ACE inhibitors and NSAIDs: the triple whammy. Med J Aust 2000 Feb 21; 172 (4): 184-5
185. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002 Oct 17; 347 (16): 1256-61
186. Bouvy ML, Heerdink ER, Hoes AW, et al. Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf 2003; 26 (13): 983-9
187. Loboz KK, Shenfield GM. Drug combinations and impaired renal function: the 'triple whammy'. Br J Clin Pharmacol 2005 Feb; 59 (2): 239-43
188. Boyd IW, Mathew TH, Thomas MC. COX-2 inhibitors and renal failure: the triple whammy revisited [letter]. Med J Aust 2000 Sep; 173 (5): 274
189. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003 Jun; 325 (6): 349-62
190. Liu BA, Juurlink DN. Drugs and the QT interval: caveat doctor. N Engl J Med 2004 Sep 9; 351 (11): 1053-6
191. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003 Jul; 23 (7): 881-908
192. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med 2000 Sep; 93 (9): 457-62
193. Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001 Apr 23; 161 (8): 1099-105
194. Tune L, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992 Oct; 149 (10): 1393-4
195. Wennmo K, Wennmo C. Drug-related dizziness. Acta Otolaryngol Suppl 1988; 455: 11-3
196. Weiner DK, Hanlon JT, Studenski SA. Effects of central nervous system polypharmacy on falls liability in community-dwelling elderly. Gerontology 1998; 44 (4): 217-21
197. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999 Jan; 47 (1): 30-9
198. Ziere G, Dieleman JP, Hofman A, et al. Polypharmacy and falls in the
199. Van der Velde N, Stricker BH, Pols HA, et al. Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol 2007 Feb; 63 (2): 232-7
200. Ensrud KE, Blackwell TL, Mangione CM, et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002 Oct; 50 (10): 1629-37
201. Landi F, Onder G, Cesari M, et al. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci 2005 May; 60 (5): 622-6
202. Wagner AK, Zhang F, Soumerai SB, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med 2004 Jul 26; 164 (14): 1567-72
203. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999 Jan; 47 (1): 40-50
204. Espino DV, Jules-Bradley AC, Johnston CL, et al. Diagnostic approach to the confused elderly patient. Am Fam Physician 1998 Mar 15; 57 (6): 1358-66
205. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999 Jul; 15 (1): 15-28
206. van Dijk KN, de Vries CS, van den Berg PB, et al. Constipation as an adverse effect of drug use in nursing home patients: an overestimated risk. Br J Clin Pharmacol 1998 Sep; 46 (3): 255-61
207. Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001 Feb; 49 (2): 200-9
208. Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006 Oct; 54 (10): 1516-23
209. Frankfort SV, Tulner LR, van Campen JP, et al. Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment at a diagnostic day clinic. Clin Drug Investig 2006; 26 (3): 169-74
210. Campbell SM, Roland MO, Shekelle PG, et al. Development of review criteria for assessing the quality of management of stable angina, adult asthma, and non-insulin dependent diabetes mellitus in general practice. Qual Health Care 1999 Mar; 8 (1): 6-15
211. Bouvy ML, Heerdink ER, Klungel OH, et al. Women with angina pectoris receive less antiplatelet treatment than men. Br J Gen Pract 1999 Apr; 49 (441): 299-300
212. Romeijnders AC, Elders PJ. Summary of the guideline 'Osteoporosis' of the Dutch College of General Practitioners: Dutch College of General Practitioners. Ned Tijdschr Geneeskd 1999 Jul 31; 143 (31): 1611-4
213. van Staa TP, Geusens P, Pols HA, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 2005 Mar; 98 (3): 191-8
214. Bouvy ML, Buurma H, Egberts TC. Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention. J Clin Pharm Ther 2002 Apr; 27 (2): 107-10
215. van Dijk KN, ter Huurne K, de Vries CS, et al. Prescribing of gastroprotective drugs among elderly NSAID users in The Netherlands. Pharm World Sci 2002 Jun; 24 (3): 100-3
216. MacRae F, MacKenzie L, McColl K, et al. How to change NSAID prescribing. Pharm J 2004; 272: 249-52
217. Do you know the SCORE [online]? Available from URL: http://www.mplan.com/ pdf/score.pdf [Accessed 2005 Dec 27]
218. Landi F, Onder G, Cesari M, et al. Pain management in frail, community-living elderly patients. Arch Intern Med 2001 Dec 10; 161 (22): 2721-4
219. Auret K, Schug SA. Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem. Drugs Aging 2005; 22 (8): 641-54
220. Hendra TJ. Starting insulin therapy in elderly patients. J R Soc Med 2002 Sep; 95 (9): 453-5
221. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23; 360 (9346): 1623-30
222. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul 6; 360 (9326): 7-22
223. Ahmed A, Kiefe CI, Allman RM, et al. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002 Oct; 50 (10): 1659-66
224. Gage BF, Fihn SD, White RH. Warfarin therapy for an octogenarian who has atrial fibrillation. Ann Intern Med 2001 Mar 20; 134 (6): 465-74
225. Ebell MH. Choosing between warfarin (coumadin) and aspirin therapy for patients with atrial fibrillation. Am Fam Physician 2005 Jun 15; 71 (12): 2348-50
226. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998 May 21; 338 (21): 1516-20
227. Schiff GD, Klass D, Peterson J, et al. Linking laboratory and pharmacy: opportunities for reducing errors and improving care. Arch Intern Med 2003 Apr 28; 163 (8): 893-900
228. Piergies AA, Worwag EM, Atkinson Jr AJ. A concurrent audit of high digoxin plasma levels. Clin Pharmacol Ther 1994 Mar; 55 (3): 353-8
229. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003 Aug; 38 (8): 843-53
230. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001 Dec 12; 286 (22): 2839-44
231. Pillans PI, Landsberg PG, Fleming AM, et al. Evaluation of dosage adjustment in patients with renal impairment. Intern Med J 2003 Jan; 33 (1-2): 10-3
232. Corsonello A, Pedone C, Corica F, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005 Apr 11; 165 (7): 790-5
233. Long CL, Raebel MA, Price DW, et al. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother 2004 May; 38 (5): 853-8
234. Van Dijk EA, Drabbe NR, Kruijtbosch M, et al. Drug dosage adjustments according to renal function at hospital discharge. Ann Pharmacother 2006; 40: 1254-60
235. Vidal L, Shavit M, Fraser A, et al. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005 Jul 30; 331 (7511): 263
236. Martin-Facklam M, Rengelshausen J, Tayrouz Y, et al. Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol 2005 Jan; 60 (11): 807-11
237. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet 1999 Nov; 37 (5): 399-431
238. Kr̈ahenb̈uhl S. Anpassen der dosierung von medikamenten bei patienten mit nieren- oder lebeinsuffizienz. Schweiz Med Wochenschr 1998 Feb 7; 128 (6): 189-94
239. Choudhury D, Ahmed Z. Drug-induced nephrotoxicity. Med Clin North Am 1997 May; 81 (3): 705-17
240. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003 Jul 31; 349 (5): 474-85
241. Jenne JW. Effect of disease states on theophylline elimination. J Allergy Clin Immunol 1986 Oct; 78 (4 Pt 2): 727-35
242. Pfeifer S. The effect of disease on the pharmacokinetics of drugs: 3. Cardiovascular, respiratory, neoplastic, thyroid diseases, diabetes, infections, mucoviscidosis, obesity, operations, burns etc. Pharmazie 1991 Dec; 46 (12): 830-9
243. Shenfield GM. Influence of thyroid dysfunction on drug pharmacokinetics. Clin Pharmacokinet 1981 Jul; 6 (4): 275-97
244. O'Connor P, Feely J. Clinical pharmacokinetics and endocrine disorders: therapeutic implications. Clin Pharmacokinet 1987 Dec; 13 (6): 345-64
245. Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003 Nov; 10 (6): 452-7
246. Justo D, Prokhorov V, Heller K, et al. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand 2005 Mar; 111 (3): 171-6
247. Brass EP, Thompson WL. Drug-induced electrolyte abnormalities. Drugs 1982 Sep; 24 (3): 207-28
248. Nanji AA. Drug-induced electrolyte disorders. Drug Intell Clin Pharm 1983 Mar; 17 (3): 175-85
249. Howes LG. Which drugs affect potassium? Drug Saf 1995 Apr; 12 (4): 240-4
250. Schwab M, Roder F, Morike K, et al. Drug-induced hyponatraemia in elderly patients. Br J Clin Pharmacol 1999 Jul; 48 (1): 105-6
251. Madhusoodanan S, Bogunovic OJ, Moise D, et al. Hyponatraemia associated with psychotropic medications: a review of the literature and spontaneous reports. Adverse Drug React Toxicol Rev 2002; 21 (1-2): 17-29
252. Ponce SP, Jennings AE, Madias NE, et al. Drug-induced hyperkalemia. Medicine (Baltimore) 1985 Nov; 64 (6): 357-70
253. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000 Sep; 109 (4): 307-14
254. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004 Aug 5; 351 (6): 543-51
255. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000 Nov 11; 356 (9242): 1667-71
256. Rogers JF, Nafziger AN, Bertino Jr JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002 Dec 15; 113 (9): 746-50
257. Van der Weide J, Steijns LS, van Weelden MJ, et al. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001 Jun; 11 (4): 287-91
258. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001 Sep; 104 (3): 173-92
259. Balis FM, Adamson PC. Application of pharmacogenetics to optimization of mercaptopurine dosing. J Natl Cancer Inst 1999 Dec 1; 91 (23): 1983-5
260. Candelaria M, Taja-Chayeb L, Arce-Salinas C, et al. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives. Anticancer Drugs 2005 Oct; 16 (9): 923-33
261. Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 2006 Aug; 27 (8): 432-7
262. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003 Feb 6; 348 (6): 538-49
263. Maitland-van der Zee AH, Klungel OH, Stricker BH, et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002 Aug; 163 (2): 213-22
264. Schelleman H, Stricker BH, de Boer A, et al. Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 2004; 64 (16): 1801-16
265. Maitland-van der Zee AH, Klungel OH, de Boer A. Pharmacogenetics in health-care practice. Pharm World Sci 2004 Oct; 26 (5): 253-5
266. Haga SB, Burke W. Using pharmacogenetics to improve drug safety and efficacy. JAMA 2004 Jun 16; 291 (23): 2869-71
267. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994 Nov 26; 344 (8935): 1453-7
268. Serretti A, Cusin C, Rausch JL, et al. Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. Psychiatry Res 2006 Nov 29; 145 (1): 61-5
269. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med 2006; 38 (2): 82-94
270. Visser LE, Van Schaik RHN, Van Vliet M, et al. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005; 77: 479-85
271. Wang LS, Zhu B, El Aty AM, et al. The influence of St John's wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004 Jun; 44 (6): 577-81
272. Burtonwood AM, Hinchliffe AL, Tinkler GS. A prescription for quality: a role for the clinical pharmacist in general practice. Pharm J 1998; 261: 678-80
273. Jameson JP, VanNoord GR. Pharmacotherapy consultation on polypharmacy patients in ambulatory care. Ann Pharmacother 2001 Jul; 35 (7-8): 835-40
274. Ellis SL, Billups SJ, Malone DC, et al. Types of interventions made by clinical pharmacists in the IMPROVE study: Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy 2000 Apr; 20 (4): 429-35
275. Britten N, Jenkins L, Barber N, et al. Developing a measure for the appropriateness of prescribing in general practice. Qual Saf Health Care 2003 Aug; 12 (4): 246-50
276. Barber N, Bradley C, Barry C, et al. Measuring the appropriateness of prescribing in primary care: are current measures complete? J Clin Pharm Ther 2005 Dec; 30 (6): 533-9
277. Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004 Mar; 59 (3): 255-63
278. Ferrucci L, Guralnik JM, Studenski S, et al. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc 2004 Apr; 52 (4): 625-34
279. Shaw SM, Opit LJ. Need for supervision in the elderly receiving long-term prescribed medication. BMJ 1976 Feb 28; 1 (6008): 505-7
280. Focus on your medicines [online]. Available from URL: http://www.npc.co.uk/med_partnership/medication-review/focus-on-your-medicines. html [Accessed 2007 Feb 14]
281. Bissell P, May CR, Noyce PR. From compliance to concordance: barriers to accomplishing a re-framed model of health care interactions. Soc Sci Med 2004 Feb; 58 (4): 851-62
282. Kerse N, Buetow S, Mainous III AG, et al. Physician-patient relationship and medication compliance: a primary care investigation. Ann Fam Med 2004 Sep; 2 (5): 455-61
283. Lau HS, Beuning KS, Postma-Lim E, et al. Non-compliance in elderly people: evaluation of risk factors by longitudinal data analysis. Pharm World Sci 1996 Apr; 18 (2): 63-8
284. McElnay JC, McCallion CR, al-Deagi F, et al. Self-reported medication non-compliance in the elderly. Eur J Clin Pharmacol 1997; 53 (3-4): 171-8
285. Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol 2001 Jun; 51 (6): 615-22
286. Avorn J. Drug prescribing, drug taking, adverse reactions, and compliance in elderly patients. In: Salzman C, editor. Geriatric clinical psychopharmacology. 3rd ed. Baltimore (MD): Williams & Wilkins, 1998
287. Blais L, Bourbeau J, Sheehy O, et al. Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatment. Can Respir J 2004 Jan; 11 (1): 27-32
288. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005 Sep; 21 (9): 1453-60
289. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005 Oct; 140 (4): 598-606
290. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005 Jul; 11 (7): 449-57
291. Van Wijk BL, Klungel OH, Heerdink ER, et al. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol 2006 Jan; 59 (1): 11-7
292. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998 Jul; 20 (4): 764-71
293. Salas M, In't Veld BA, van der Linden PD, et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther 2001 Dec; 70 (6): 561-6
294. Kilbourne AM, Reynolds III CF, Good CB, et al. How does depression influence diabetes medication adherence in older patients? Am J Geriatr Psychiatry 2005 Mar; 13 (3): 202-10
295. Horne R. Patients' beliefs about treatment: the hidden determinant of treatment outcome? J Psychosom Res 1999 Dec; 47 (6): 491-5
296. Horne R, Clatworthy J, Polmear A, et al. Do hypertensive patients' beliefs about their illness and treatment influence medication adherence and quality of life? J Hum Hypertens 2001 Aug; 15 Suppl. 1: S65-8
297. Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005 Jul; 61 (1): 133-55
298. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997 Jan; 50 (1): 105-16
299. Paes AH, Bakker A, Soe-Agnie CJ. Measurement of patient compliance. Pharm World Sci 1998 Apr; 20 (2): 73-7
300. Grymonpre RE, Didur CD, Montgomery PR, et al. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother 1998 Jul; 32 (7-8): 749-54
301. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999 Sep; 37 (9): 846-57
302. Vrijens B, Belmans A, Matthys K, et al. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 2006 Feb; 15 (2): 115-21
303. Wetzels GE, Nelemans PJ, Schouten JS, et al. Electronic monitoring of adherence as a tool to improve blood pressure control a randomized controlled trial. Am J Hypertens 2007 Feb; 20 (2): 119-25
304. Bova CA, Fennie KP, Knafl GJ, et al. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav 2005 Mar; 9 (1): 103-10
305. MacLaughlin EJ, Raehl CL, Treadway AK, et al. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging 2005; 22 (3): 231-55
306. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002 Dec 11; 288 (22): 2868-79
307. Van Eijken M, Tsang S, Wensing M, et al. Interventions to improve medication compliance in older patients living in the community: a systematic review of the literature. Drugs Aging 2003; 20 (3): 229-40
308. Elliott RA, Barber N, Horne R. Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence. Ann Pharmacother 2005 Mar; 39 (3): 508-15
309. Cramer JA. Enhancing patient compliance in the elderly: role of packaging aids and monitoring. Drugs Aging 1998 Jan; 12 (1): 7-15
310. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 Aug; 23 (8): 1296-310
311. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002 Mar; 24 (3): 460-7
312. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62 (3): 443-62
313. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ 2004 Dec; 82 (12): 935-9
314. Rivers PH. Compliance aids: do they work? Drugs Aging 1992 Mar; 2 (2): 103-11
315. Corlett AJ. Aids to compliance with medication. BMJ 1996 Oct 12; 313 (7062): 926-9
316. Nunney JM, Raynor DK. How are multi-compartment compliance aids used in primary care? Pharm J 2001; 267: 784-9
317. Raynor DK, Nunney JM. Medicine compliance aids are partial solution, not panacea [letter]. BMJ 2002 Jun 1; 324 (7349): 1338
318. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006 Dec 6; 296 (21): 2563-71
319. Diette GB, Wu AW, Skinner EA, et al. Treatment patterns among adult patients with asthma: factors associated with overuse of inhaled beta-agonists and underuse of inhaled corticosteroids. Arch Intern Med 1999 Dec 13; 159 (22): 2697-704
320. Finfgeld-Connett DL. Treatment of substance misuse in older women: using a brief intervention model. J Gerontol Nurs 2004 Aug; 30 (8): 30-7
321. MacFadyen L, Eadie D, McGowan T. Community pharmacists' experience of over-the-counter medicine misuse in Scotland. J R Soc Health 2001 Sep; 121 (3): 185-92
322. Motola G, Mazzeo F, Rinaldi B, et al. Self-prescribed laxative use: a drug-utilization review. Adv Ther 2002 Sep; 19 (5): 203-8
323. Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998 Nov; 56 (5): 811-24
324. Hallas J, Lauritsen J, Villadsen HD, et al. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995 May; 30 (5): 438-44
325. Visser LE, Graatsma HH, Stricker BH. Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease. Br J Clin Pharmacol 2002 Feb; 53 (2): 183-8
326. van der Linden CM, Kerskes MC, Bijl AM, et al. Represcription after adverse drug reaction in the elderly: a descriptive study. Arch Intern Med 2006 Aug 14; 166 (15): 1666-7
327. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999 Jun; 36 (6): 425-38
328. De Smet PAGM. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004 Jul; 76 (1): 1-17
329. Mynors G, Ghalamkari H, Beaumont S, et al. Informed choice in medicine taking: drugs of porcine origin and their clinical alternatives: an introductory guide. London: Medicines Partnership, 2004
330. Aadil N, Houti IE, Moussamih S. Drug intake during Ramadan. BMJ 2004 Oct 2; 329 (7469): 778-82
331. Al Arouj M, Bouguerra R, Buse J, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care 2005 Sep; 28 (9): 2305-11
332. Pickering G. Frail elderly, nutritional status and drugs. Arch Gerontol Geriatr 2004 Mar; 38 (2): 174-80
333. Golden AG, Petropoulos JB, Silverman MA, et al. The use of oral nutritional supplements and anorexigenic medications in homebound older adults. J Am Geriatr Soc 2003 May; 51 (5): 724-6
334. Lisberg RB, Higham C, Jayson MI. Problems for rheumatic patients in opening dispensed drug containers. Br J Rheumatol 1983 May; 22 (2): 95-8
335. Verheggen-Laming BN, Phiferons H, Mulder EF, et al. Comparison of packages for suppositories by patients with rheumatoid arthritis. Scand J Rheumatol 1988; 17 (3): 161-5
336. Diggory P, Fernandez C, Humphrey A, et al. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001 Mar 10; 322 (7286): 577-9
337. Ho SF, O'Mahony MS, Steward JA, et al. Inhaler technique in older people in the community. Age Ageing 2004 Mar; 33 (2): 185-8
338. Dow L, Fowler L, Lamb H. Elderly people's technique in using dry powder inhalers: new inhaler devices are rarely used by older people in the community. BMJ 2001 Jul 7; 323 (7303): 49-50
339. Allen SC, Jain M, Ragab S, et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. Age Ageing 2003 May; 32 (3): 299-302
340. McDonald VM, Gibson PG. Inhalation-device polypharmacy in asthma. Med J Aust 2005 Mar 7; 182 (5): 250-1
341. Winfield AJ, Jessiman D, Williams A, et al. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol 1990 Aug; 74 (8): 477-80
342. Burns E, Mulley GP. Practical problems with eye-drops among elderly ophthalmology outpatients. Age Ageing 1992 May; 21 (3): 168-70
343. Busche S, Gramer E. Verbesserung der augentropfenapplikation und compliance bei glaukompatienten: eine klinische studie. Klin Monatsbl Augenheilkd 1997 Oct; 211 (4): 257-62
344. Van Drooge MJ, De Smet PAGM. Hoe glaucoompatiënten oogdruppels gebruiken: instructieprotocol onderzocht in proefproject. Pharm Weekbl 2000; 135: 1016-20
345. Blickle JF, Attali JR, Barrou Z, et al. Le diabète du sujet âgé. Diabetes Metab 1999 Mar; 25 (1): 84-93
346. Jehle PM, Micheler C, Jehle DR, et al. Inadequate suspension of neutral protamine hagendorn (NPH) insulin in pens. Lancet 1999 Nov 6; 354 (9190): 1604-7
347. Brown A, Steel JM, Duncan C, et al. An assessment of the adequacy of suspension of insulin in pen injectors. Diabet Med 2004 Jun; 21 (6): 604-8
348. De Smet PAGM, Van de Vaart FJ. De ontwikkeling van het beroep. Pharm Weekbl 2006; 141: 1278
349. Simon SR, Gurwitz JH. Drug therapy in the elderly: improving quality and access. Clin Pharmacol Ther 2003 May; 73 (5): 387-93
350. Royal S, Smeaton L, Avery AJ, et al. Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis. Qual Saf Health Care 2006 Feb; 15 (1): 23-31
351. Holland R, Smith R, Harvey I. Where now for pharmacist led medication review? J Epidemiol Community Health 2006 Feb; 60 (2): 92-3
352. Howard RL, Avery AJ. Pharmacist-led medication reviews can reduce patient morbidity? Age Ageing 2006 Nov; 35 (6): 555-6
353. Schmader KE, Hanlon JT, Pieper CF, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med 2004 Mar 15; 116 (6): 394-401
354. Mannheimer B, Ulfvarson J, Eklof S, et al. Drug-related problems and pharmacotherapeutic advisory intervention at a medicine clinic. Eur J Clin Pharmacol 2006 Dec; 62 (12): 1075-81